ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Total Current Liabilities
ExpreS2ion Biotech Holding AB
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Total Current Liabilities
kr27.1m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Current Liabilities
kr199.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Current Liabilities
kr162.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Current Liabilities
kr615m
|
CAGR 3-Years
0%
|
CAGR 5-Years
28%
|
CAGR 10-Years
17%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Current Liabilities
kr16.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
28%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Current Liabilities
kr520.8m
|
CAGR 3-Years
94%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Total Current Liabilities?
Total Current Liabilities
27.1m
SEK
Based on the financial report for Sep 30, 2025, ExpreS2ion Biotech Holding AB's Total Current Liabilities amounts to 27.1m SEK.
What is ExpreS2ion Biotech Holding AB's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-3%
Over the last year, the Total Current Liabilities growth was -18%. The average annual Total Current Liabilities growth rates for ExpreS2ion Biotech Holding AB have been 13% over the past three years , -3% over the past five years .
